Loading resource…

S. Maria della Misericordia Hospital, Perugia, Italy; University of Insubria, Varese, Italy
Metformin has long been a cornerstone in the management of Type 2 diabetes due to its glycemic control and cardiovascular risk reduction properties. However, recent studies have shown that gliflozines, a class of drugs that inhibit renal glucose reabsorption, offer significant cardio-renal benefits that may surpass those of metformin. The document reviews various clinical trials that demonstrate the efficacy of gliflozines in reducing cardiovascular events and improving renal outcomes, even in patients without diabetes. It also discusses the differing recommendations from various guidelines regarding the use of these medications in clinical practice.
No account needed